Last reviewed · How we verify
Improving Resorption of Radiopaque Agents in Subcutaneous Urography — Treatment Landscape & Competitive Intelligence
1 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Recombinant antithrombin (rhAT) | Recombinant antithrombin (rhAT) | Mayo Clinic | Dispersion agent; enzyme | Hyaluronic acid and connective tissue polysaccharides |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- Mayo Clinic · 1 drug in Improving Resorption of Radiopaque Agents in Subcutaneous Urography
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Improving Resorption of Radiopaque Agents in Subcutaneous Urography:
- Improving Resorption of Radiopaque Agents in Subcutaneous Urography treatment updates — RSS
- Improving Resorption of Radiopaque Agents in Subcutaneous Urography treatment updates — Atom
- Improving Resorption of Radiopaque Agents in Subcutaneous Urography treatment updates — JSON
Cite this brief
Drug Landscape (2026). Improving Resorption of Radiopaque Agents in Subcutaneous Urography — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/improving-resorption-of-radiopaque-agents-in-subcutaneous-urography. Accessed 2026-06-10.
Related
- Improving Resorption of Radiopaque Agents in Subcutaneous Urography full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing